J Psychopharmacol 2014 Baldwin 403 39

Topics: Anxiety disorder, Panic disorder, Anxiety disorders Pages: 37 (36165 words) Published: April 12, 2015
525674
research-article2014

JOP0010.1177/0269881114525674Journal of PsychopharmacologyBaldwin et al.

BAP Guidelines

Evidence-based pharmacological treatment
of anxiety disorders, post-traumatic stress
disorder and obsessive-compulsive disorder:
A revision of the 2005 guidelines from the
British Association for Psychopharmacology

Journal of Psychopharmacology
2014, Vol. 28(5) 403­–439
© The Author(s) 2014
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0269881114525674
jop.sagepub.com

David S Baldwin1,2, Ian M Anderson3, David J Nutt4, Christer Allgulander5, Borwin Bandelow6, Johan A den Boer7,8, David M Christmas9, Simon Davies10, Naomi Fineberg11, Nicky Lidbetter12, Andrea Malizia13, Paul McCrone14, Daniel Nabarro15, Catherine O’Neill12, Jan Scott16, Nic van der Wee17 and Hans-Ulrich Wittchen18

Abstract
This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

Keywords
Anticonvulsants, antidepressants, antipsychotics, anxiety disorders, anxiolytics, benzodiazepines, cognitive behaviour therapy, evidence-based guidelines, generalised anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, pregabalin, separation anxiety disorder, serotonin-noradrenaline reuptake inhibitor, social anxiety disorder, specific phobia, selective serotonin reuptake inhibitor, treatment.

1. Introduction
The British Association for Psychopharmacology (BAP; www.
bap.org.uk) aims to advance education and research in the science and practice of psychopharmacology by arranging scientific

meetings, fostering research and teaching, encouraging publication of research results, and providing guidance and information on matters relevant to psychopharmacology. As part of this

1Faculty

11Postgraduate

2Department

12Anxiety

of Medicine, University of Southampton, Southampton, UK
of Psychiatry and Mental Health, University of Cape Town,
Cape Town, South Africa
3Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
4Division of Experimental Medicine, Imperial College London, London, UK
5Karolinska Institutet, Stockholm, Sweden
6Department of Psychiatry and Psychotherapy, University of
Goettingen, Goettingen, Germany
7Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen (UMCG), Groningen, The Netherlands
8PRA International Zuidlaren,The Netherlands
9Cambridge and Peterborough NHS Foundation Trust, Cambridge, UK 10Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada

Medical School, University of Hertfordshire, Hatfield, UK
UK, Manchester, UK
13North Bristol NHS Trust, Bristol, UK
14Institute of Psychiatry, Kings College London, London, UK
15OCD Action, London, UK
16Newcastle University, Newcastle, UK
17Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
18Institute of Clinical Psychology and Psychotherapy, Technical University Dresden, Dresden, Germany
Corresponding author:
David Baldwin, University Department of Psychiatry,...

References: Abrantes AM, Strong DR, Cohn A, et al. (2009) Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. J Anxiety
Disord 23: 923–927.
Ackerman DL and Greenland S (2002) Multivariate meta-analysis of
controlled drug studies for obsessive-compulsive disorder
Aderka IM, Hofmann SG, Nickerson A, et al. (2012) Functional impairment in social anxiety disorder. J Anxiety Disord 26: 393–400.
Alamy S, Wei Z, Varia I, et al (2008) Escitalopram in specific phobia:
Results of a placebo-controlled pilot trial
Albus M and Scheibe G (1993) Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow-up study.
Allgulander C, Dahl AA, Austin C, et al. (2004a) Efficacy of sertraline
in a 12-week trial for generalized anxiety disorder
Allgulander C, Mangano R, Zhang J, et al. (2004b) Efficacy of Venlafaxine ER in patients with social anxiety disorder: A double-blind,
placebo-controlled, parallel-group comparison with paroxetine
Alper K, Schwartz KA, Kolts RL, et al. (2007) Seizure incidence in
psychopharmacological clinical trials: An analysis of food and drug
Altamura AC, Serati M, Buoli M, et al. (2011) Augmentative quetiapine
in partial/nonresponders with generalized anxiety disorder: A randomized, placebo-controlled study
American Psychiatric Association (1994) Diagnostic and Statistical
Manual of Mental Disorders Washington, DC: American Psychiatric Association.
American Psychiatric Association (2013) Diagnostic and Statistical
Manual of Mental Disorders (DSM-5)
Amsterdam JD, Li Y, Soeller I, et al. (2009) A randomized, double-blind,
placebo-controlled trial of oral matricaria recutita (chamomile)
Anderson I, Ferrier I, Baldwin R, et al. (2008) Evidence-based guidelines
for treating depressive disorders with antidepressants: A revision of
Anderson IM, Nutt DJ and Deakin JFW (2000) Evidence-based guidelines for treating depressive disorders with antidepressants, a revision
of the 1993 British Association for Psychopharmacology guidelines.
Andersson E, Enander J, Andren P, et al. (2012) Internet-based cognitive
behaviour therapy for obsessive-compulsive disorder: A randomized
Andersson G (2012) Guided internet treatment for anxiety disorders. As
effective as face-to-face therapies? Stud Health Technol Inform 181:
Andlin-Sobcki P and Wittchen HU (2005) Cost of anxiety disorders in
Europe
Andrews G and Carter GL (2001) What people say about their general
practitioners’ treatment of anxiety and depression
Andrisano C, Chiesa A and Serretti A (2013) Newer antidepressants
and panic disorder: A meta-analysis
Angst J, Gamma A, Baldwin DS, et al. (2009) The generalized anxiety
spectrum: Prevalence, onset, course and outcome
Askari N, Moin M, Sanati M, et al. (2012) Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder a
randomized, double-blind, placebo-controlled trial
Baldwin D, Anderson I, Nutt D, et al. (2005) Evidence-based guidelines
for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology
Baldwin D, Woods R, Lawson R, et al. (2011a) Efficacy of drug treatments for generalised anxiety disorder: Systematic review and metaanalysis. Brit Med J 342: d1199.
Baldwin DS and Kosky N (2007) Off-label prescribing in psychiatric
practice
Baldwin DS and Talat B (2012) Should benzodiazepines still have a role
in treating patients with anxiety disorders? Hum Psychopharmacol
Baldwin DS, Ajel K, Masdrakis VG, et al. (2013) Pregabalin for the treatment of generalized anxiety disorder: An update. Neuropsychiatr Dis
Treat 9: 883–892.
Baldwin DS, Allgulander C, Altamura AC, et al. (2010) Manifesto for a
European Anxiety Disorders Research Network
Baldwin DS, Loft H and Florea I (2012) Lu AA21004, a multimodal
psychotropic agent, in the prevention of relapse in adult patients
Baldwin DS, Montgomery SA, Nil R, et al. (2007) Discontinuation
symptoms in depression and anxiety disorders
Baldwin DS, Stein DJ, Dolberg OT, et al. (2009) How long should a
trial of escitalopram treatment be in patients with major depressive
Baldwin DS, Waldman S and Allgulander C (2011b) Evidence-based
pharmacological treatment of generalized anxiety disorder
Ballenger JC (1998) New treatments for panic. Eur Psychiatry 13: 75s–81s.
Ballenger JC, Wheadon DE, Steiner M, et al. (1998) Double-blind, fixeddose, placebo-controlled study of paroxetine in the treatment of
panic disorder
Bandelow B, Seidler-Brandler U, Becker A, et al. (2007a) Meta-analysis
of randomized controlled comparisons of psychopharmacological
Bandelow B, Stein DI, Dolberg OT, et al. (2007b) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo.
Post-Traumatic Stress Disorders. (2008a) World Federation of
Societies of Biological Psychiatry (WFSBP) guidelines for the
Bandelow B, Zohar J, Hollander E, et al. (2008b) World Federation
of Societies of Biological Psychiatry (WFSBP) guidelines for the
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • Baldwin Essay
  • Word 2014 Essay
  • J&J Brazil Analysis Essay
  • J and J Case Study Essay
  • J the Dot J Essay
  • Essay about J&J Swot
  • J J Creative Brief Essay
  • James Baldwin Essay

Become a StudyMode Member

Sign Up - It's Free